Literature DB >> 19727565

Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome.

A Wick, N Schäfer, N Dörner, D Schemmer, M Platten, M Bendszus, W Wick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19727565     DOI： 10.1007/s11060-009-0003-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  5 in total

1.  Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

Authors:  P Bono; H Elfving; T Utriainen; P Osterlund; T Saarto; T Alanko; H Joensuu
Journal:  Ann Oncol       Date:  2009-02       Impact factor: 32.976

2.  Hypertension as a surrogate marker for the activity of anti-VEGF agents.

Authors:  O Mir; S Ropert; J Alexandre; F Goldwasser
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

4.  Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

Authors:  Marc C Chamberlain; Sandra K Johnston
Journal:  J Neurooncol       Date:  2009-07-11       Impact factor: 4.130

5.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

Authors:  Antje Wick; Jörg Felsberg; Joachim P Steinbach; Ulrich Herrlinger; Michael Platten; Britta Blaschke; Richard Meyermann; Guido Reifenberger; Michael Weller; Wolfgang Wick
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544
  5 in total
  8 in total

1.  Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab.

Authors:  Shubham Pant; Ludmila K Martin; Susan Geyer; Lai Wei; Katherine Van Loon; Nili Sommovilla; Mark Zalupski; Renuka Iyer; David Fogelman; Andrew H Ko; Tanios Bekaii-Saab
Journal:  Am J Clin Oncol       Date:  2016-12       Impact factor: 2.339

2.  Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.

Authors:  Ahmad A Tarhini; Paul Frankel; Kim A Margolin; Scott Christensen; Christopher Ruel; Janice Shipe-Spotloe; David R Gandara; Alice Chen; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2011-08-31       Impact factor: 12.531

Review 3.  Off-tumor target--beneficial site for antiangiogenic cancer therapy?

Authors:  Yihai Cao
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

4.  Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.

Authors:  Elisabeth Bumes; Sarah Rzonsa; Markus Hutterer; Martin Proescholdt; Ulrich Bogdahn; Markus J Riemenschneider; Martin Uhl; Christina Wendl; Peter Hau
Journal:  J Neurooncol       Date:  2015-12-31       Impact factor: 4.130

5.  Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat.

Authors:  Annelise Letourneur; Simon Roussel; Myriam Bernaudin; Fabien Fillesoye; Jérôme Toutain; Eric T MacKenzie; Edwige Petit; Omar Touzani; Samuel Valable
Journal:  Hypertens Res       Date:  2015-06-18       Impact factor: 3.872

6.  Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.

Authors:  Bruno Vincenzi; Daniele Santini; Antonio Russo; Raffaele Addeo; Francesco Giuliani; Liliana Montella; Sergio Rizzo; Olga Venditti; Anna Maria Frezza; Michele Caraglia; Giuseppe Colucci; Salvatore Del Prete; Giuseppe Tonini
Journal:  Oncologist       Date:  2010-01-05

Review 7.  Bevacizumab for glioblastoma.

Authors:  Yoshitaka Narita
Journal:  Ther Clin Risk Manag       Date:  2015-12-01       Impact factor: 2.423

Review 8.  Hypertension in malignancy-an underappreciated problem.

Authors:  Jolanta Małyszko; Maciej Małyszko; Leszek Kozlowski; Klaudia Kozlowska; Jacek Małyszko
Journal:  Oncotarget       Date:  2018-04-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.